Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Non-Randomized, Open-Label, Dose Escalation, Single-Center Study to Determine the Safety, Bio-distribution, and Preliminary Effectiveness of AlphaMedix™ in Adult Subjects With SSRT(+) NETs.

Trial Profile

A Phase 1, Non-Randomized, Open-Label, Dose Escalation, Single-Center Study to Determine the Safety, Bio-distribution, and Preliminary Effectiveness of AlphaMedix™ in Adult Subjects With SSRT(+) NETs.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2019

At a glance

  • Drugs 212-Pb-AR-RMX (Primary)
  • Indications Neuroendocrine tumours
  • Focus Adverse reactions; First in man
  • Sponsors RadioMedix
  • Most Recent Events

    • 22 Jan 2019 According to a RadioMedix media release, Dr. Izabela Tworowska (RadioMedix) serves as a Principal Investigator of the SBIR Phase II Contract and working together with Dr. Julien Torgue (co-I, Orano Med).
    • 22 Jan 2019 According to a RadioMedix media release, a $2.0 M Phase II SBIR contract award by the NIH NCI (HHSN261201800048C; UPIID:75N91018C00048) for the clinical development of Targeted Alpha-emitter Therapy (TAT) of neuroendocrine tumors, will support this study. This Phase II Contract award is a continuation of the successfully completed Phase I SBIR contract (HHSN261201600015C).
    • 20 Feb 2018 According to an Orano Med media release, the first three patients have been dosed in this Phase 1 clinical trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top